Press "Enter" to skip to content

Canagliflozin to Serve as a Major Landmark in Diabetes Treatment

According to the World Health Organization, diabetic patients have risen from 108 million in 1980 to 422 million in 2014. This number may further rise 20 percent to 510 million in 2030. People with diabetes are at a great risk of kidney failure and high blood pressure. This is due to high blood sugar that harms blood vessels in the kidney. A new study suggests the drug canagliflozin remarkably reduces the risk of kidney failure in people with type 2 diabetes. Moreover, it lowers the risk of kidney failure in people with chronic kidney disease.

New Drug to Enhance the RAAS Blockade Therapy

The researchers involved in this study conducted a trial with 4,401 participants from 34 countries. These participants received the renin-angiotensin-aldosterone system therapy also known as RAAS, blockade. Additionally, half of the participants received canagliflozin while the others received placebo. The results suggested that the participants consuming canagliflozin were 30 percent less likely to die of renal failure. Moreover, their risk of kidney failure has subsided 34 percent and that of heart failure 31 percent. Researchers further demonstrated that the new drug enhanced the RAAS blockade therapy. Although, RAAS blockade reduces the blood pressure it does not provide protection against renal failure.

Kenneth Mahaffey, MD, professor of medicine at the School of Medicine said that canagliflozin enhances both renal and cardiovascular outcomes. Further, he said that this drug is popular among the Type 2 diabetes patients and the doctors treating these patients. The Food and Drug Administration has now approved this drug to reduce the risk of cardiovascular diseases in Type 2 Diabetes patients.

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Be First to Comment

Leave a Reply